Dossier
atumelnant
Coverage of atumelnant in the Nexus archive.
- Vertex Pharmaceuticals is buying Crinetics to expand into rare hormonal diseases
Vertex Pharmaceuticals is acquiring Crinetics to expand into rare hormonal diseases. The deal provides access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia.